(ZH) How Bad Could It Get? US Government Order Of 160,000 HazMat Suits Gives A C

{http://www.prnewswire.com/news-releases/lakeland-industries-announces-global-availability-of-hazmat-suits-for-ebola-274892141.html}

How Bad Could It Get? US Government Order Of 160,000 HazMat Suits Gives A Clue

Now that Ebola is officially in the US on an uncontrolled basis, the two questions on everyone's lips are i) who will get sick next and ii) how bad could it get?
We don't know the answer to question #1 just yet, but when it comes to the second one, a press release three weeks ago from Lakeland Industries, a manufacturer and seller of a "comprehensive line of safety garments and accessories for the industrial protective clothing market" may provide some insight into just how bad the US State Department thinks it may get. Because when the US government buys 160,000 hazmat suits specifically designed against Ebola, just ahead of the worst Ebola epidemic in history making US landfall, one wonders: what do they know the we don't?
Lakeland Industries, Inc. (LAKE), a leading global manufacturer of industrial protective clothing for industry, municipalities, healthcare and to first responders on the federal, state and local levels, today announced the global availability of its protective apparel for use in handling the Ebola virus. In response to the increasing demand for specialty protective suits to be worm by healthcare workers and others being exposed to Ebola, Lakeland is increasing its manufacturing capacity for these garments and includes proprietary processes for specialized seam sealing, a far superior technology for protecting against viral hazards than non-sealed products.
"Lakeland stands ready to join the fight against the spread of Ebola," said Christopher J. Ryan, President and Chief Executive Officer of Lakeland Industries. "We understand the difficulty of getting appropriate products through a procurement system that in times of crisis favors availability over specification, and we hope our added capacity will help alleviate that problem. With the U.S. State Department alone putting out a bid for 160,000 suits, we encourage all protective apparel companies to increase their manufacturing capacity for sealed seam garments so that our industry can do its part in addressing this threat to global health.
Of course, purchases by the US government are bought and paid for by taxpayers. For everyone else there's $1200 mail-order delivery:
That said... 160,000 HazMats for a disease that is supposedly not airborne? Mmmk.

>>>JDSU - Spinking on Sandell letter to the board

Sandell Asset Management Releases Letter to the Board of Directors of JDS Uniphase 
ubmits Shareholder Proposal that JDS Uniphase Evaluate Further Strategic Alternatives to Maximize the Value of its Business and Tax Assets

Estimates Potential Value at Between $19 and $26 per Share

>>> US Gapping down

Gapping down In reaction to disappointing earnings/guidance: WPRT -24.8%, ASEI -6.3%, AZZ -5.4%

Select air carriers names showing weakness: UAL -2.8%, HA -1.9%, DAL -1.9%, JBLU -1.7%, AAL -1.6%, LUV -1.5%.

Select metals/mining stocks trading lower: MT -1.5%, CLF -0.8%, BHP -0.7%

Select oil/gas related names showing early weakness: PBR -3.4%, SDRL -2.4%, MRO -1.4%, RDS.A -1.1%, RIG -0.9%, TOT -0.7%, E -0.6%, BP -0.5%

Other news: FNMA -60.2% (following dismissal of lawsuit brought by Perry Capital LLC and Fairholme Funds), FMCC -60.2% (following dismissal of lawsuit brought by Perry Capital LLC and Fairholme Funds), SPEX -17.3% (announces Markman hearing date for VTech and Uniden litigation now set for Nov 10, 2014; originally expected to occur Oct 2, 2014), RGSE -4.1% (announces strategy to exit large commercial business), CYBR -2.7% (cont momentum following recent IPO launch), GPRO -2.1% (cont vol pre-mkt), SYT -2.1% (cont weakness), BUD -1.5% (still checking)

Analyst comments: TUES -3.3% (downgraded to Neutral from Outperform at Credit Suisse), EBAY -2.4% (downgraded to Neutral at JP Morgan, among others), CRK -0.9% (downgraded to Hold at Stifel), JNJ -0.6% (downgraded to Mkt Perform from Outperform at Bernstein)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance: SYNC +7.3%, (reaffirms Q3 guidance; raises FY14 EBITDA guidance; revises strategic plan)

M&A news: ANGI +20.7% (FT reports co hired bankers to explore alternatives, including sale), AKRX +1.3% (acquires Xopenenx Inhalation Soplutions for approx $45 mln in cash; expects this transaction to add ~$18 million to $20 million in revenues and approximately $0.07 to $0.08 of net income per diluted share in 2015)

Select Ebola related names showing strength after CDC confirmed ebola case diagnosed in the US: TKMR +26.8%, HEB +21.9%, LAKE +12.2%, NNVC +10%, NLNK +9.5%, BCRX +8.4%, SRPT +6.6%, INO +5.1%.

Other news: MTL +16.8% (extending yesterday's gains boosted by positive VTB comments), CGEN +5.1% (discloses new results for novel target candidate for cancer immunotherapy; recent data further support CGEN-15049 immune checkpoint role in inhibiting the immune response to cancer cells), RTRX +3.1% (still checking), APP +2.4% (may keep Dov Charney on Board, according to reports), KERX +1.5% (announces issuance of a new U.S. patent for ferric citrate covering orally administrable forms), VE +1.2% (still checking), WAG +1.2% (Express Scripts collaborates with Walgreens (WAG) to create Medicare Prescription Drug Plan pharmacy network), BBRY +1.2% (still checking), .

Analyst comments: AGN +2.1% (upgraded to Buy at Stifel), DYN +1.9% (upgraded to Buy from Neutral at ISI Group), OWW +1.9% (upgraded to Outperform at Oppenheimer), JNS +1.4% (upgraded to Buy from Hold at Jefferies)

Fwd:>>> Airbus - Stock trading higher today, testing its 200d MA...

stock trading on the 49 level -25 since this morning, could see some sellers as 200d MA appear to be a strong resistance...and market trading lower

From: LAURENT CHEKROUN () At: Oct 1 2014 09:25:22
Subject: Fwd:>>> Airbus - Stock trading higher today, testing its 200d MA...
It will be an interesting day on the name, I will be more cautious arround here as so far we saw few PW in cyclical, Basic mat, trading down...not sure investors have very high expectations for Growth on next few months ...after Being aggressively buyer on the name lower (43/44) I will take profit here...I see limited upside 3/4% and more downisde if heavy downturn on market

(Stifel) Allergan upgraded to Buy at Stifel; tgt $200

Allergan upgraded to Buy at Stifel; tgt $200

Stifel upgrades AGN to Buy from Hold and sets target price at $200. AGN continues to resist overtures from VRX (at $72/share cash, 0.83/1.227 exchange ratio). The total value ranges between $175-180 and $220+, considering the theoretical PF value of the combined AGN-VRX entity. AGN maintains that VRX's offer is "grossly inadequate" and has pursued its own strategy to enhance value by 1) driving business performance, 2) executing a restructuring plan, 3) generating pipeline value, and 4) pursuing capital allocation through B/S leverage (with M&A as the ultimate strategy). They believe that AGN retains several options at its disposal to generate greater shareholder return than the VRX offer. They look for developments prior to the 12/18/14 Special Meeting.